Journal: bioRxiv

Article Title: CRISPR-based screens uncover determinants of immunotherapy response in Multiple Myeloma

doi: 10.1101/833707

Figure Lengend Snippet: A , BCMA-ADC cytotoxicity dose-response assay of CRISPRi KMS11 cells expressing two independent sgRNA targeted towards BCMA and a non-targeting control sgRNA. B, KMS11 cells treated with indicated concentrations of PS3061 and RO4929097 were stained for BCMA and analyzed by flow cytometry. Histograms indicate the distribution of BCMA. Data is a representation of two biological replicates. C, BCMA-ADC cytotoxicity dose-response assay was performed in combination with indicated concentrations of drugs. Data points are means of two biological replicates; error bars denote SD. D, KMS11 cells treated with indicated concentrations of PS3061 and 2.5 μM RO4929097 were stained for BCMA and analyzed by flow cytometry. Data is a representation of two biological replicates; error bars denote SD. E, BCMA-ADC cytotoxicity dose-response assay was performed in combination with indicated concentrations of drugs. Data points are means of two biological replicates; error bars denote SD.

Article Snippet: We obtained an ADC targeting BCMA, HDP101 , , developed by Heidelberg Pharma that has proven efficacy in MM cell lines at sub-nanomolar concentrations (unpublished data).

Techniques: Expressing, Staining, Flow Cytometry

Journal: Pharmaceuticals

Article Title: Antibody–Drug Conjugates: The Last Decade

doi: 10.3390/ph13090245

Figure Lengend Snippet: Antibody–drug conjugates (ADCs) approved by the Food and Drug Administration (FDA), in advanced clinical trials (Phase III or pivotal phase II) or recently stopped.

Article Snippet: In order to obtain potent antitumor activity in cancer cells with a wider range of HER2 expression, the biparatopic ADC IMMU4276 targeting HER2 was developed by MedImmune ( ) [ ].

Techniques: Clinical Proteomics

Journal: Pharmaceuticals

Article Title: Antibody–Drug Conjugates: The Last Decade

doi: 10.3390/ph13090245

Figure Lengend Snippet: Homogeneous ADC with a DAR 4 comprising a biparatopic anti-HER2 antibody conjugated to a tubulysin derivative via a classical maleimidocaproic linker.

Article Snippet: In order to obtain potent antitumor activity in cancer cells with a wider range of HER2 expression, the biparatopic ADC IMMU4276 targeting HER2 was developed by MedImmune ( ) [ ].

Techniques:

Journal: Pharmaceuticals

Article Title: Antibody–Drug Conjugates: The Last Decade

doi: 10.3390/ph13090245

Figure Lengend Snippet: SYD985 formula, anti-HER2 trastuzumab conjugated to seco -DUBA via a cleavable linker sensitive to cathepsin B.

Article Snippet: In order to obtain potent antitumor activity in cancer cells with a wider range of HER2 expression, the biparatopic ADC IMMU4276 targeting HER2 was developed by MedImmune ( ) [ ].

Techniques:

Journal: Pharmaceuticals

Article Title: Antibody–Drug Conjugates: The Last Decade

doi: 10.3390/ph13090245

Figure Lengend Snippet: Enhertu ® (fam-trastuzumab deruxtecan-nxki or DS-8201a) formula, ADC with a DAR 7.7, resulting from anti-HER2 trastuzumab conjugation to exatecan DX-8951 via a linker sensitive to proteolysis.

Article Snippet: In order to obtain potent antitumor activity in cancer cells with a wider range of HER2 expression, the biparatopic ADC IMMU4276 targeting HER2 was developed by MedImmune ( ) [ ].

Techniques: Conjugation Assay